AGTX Stock Overview
A clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Agentix Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.05 |
| 52 Week High | US$0.09 |
| 52 Week Low | US$0.021 |
| Beta | -1.4 |
| 11 Month Change | 85.19% |
| 3 Month Change | 91.57% |
| 1 Year Change | -30.07% |
| 33 Year Change | -95.45% |
| 5 Year Change | n/a |
| Change since IPO | -98.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| AGTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | 0.8% |
| 1Y | -30.1% | 21.6% | 33.4% |
Return vs Industry: AGTX underperformed the US Pharmaceuticals industry which returned 20.9% over the past year.
Return vs Market: AGTX underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| AGTX volatility | |
|---|---|
| AGTX Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AGTX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AGTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | n/a | www.agentixcorp.com |
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. The company offers AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019.
Agentix Corp. Fundamentals Summary
| AGTX fundamental statistics | |
|---|---|
| Market cap | US$503.35k |
| Earnings (TTM) | -US$326.31k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs AGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$326.31k |
| Earnings | -US$326.31k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -6.0% |
How did AGTX perform over the long term?
See historical performance and comparison